Crocs's stock drops on Q3 profit warning
By Steve Gelsi
Footwear maker's share price gives back some of its 44% gain so far this year
Crocs Inc.'s stock was down about 5% Thursday after the footwear company warned its profit in the coming quarter may be weaker than expected, even as second-quarter earnings beat Wall Street expectations.
Crocs (CROX) said its profit for the three months ending June 30 rose to $228.9 million, or $3.77 a share, from $212.4 million, or $3.39 a share, in the year-ago quarter.
Adjusted second-quarter earnings of $4.01 a share handily beat the FactSet consensus estimate of $3.55 a share.
Second-quarter revenue rose to $1.11 billion from $1.07 billion and narrowly beat the analyst estimate of $1.1 billion.
For the third quarter, Crocs said it expects adjusted earnings of $2.95 a share to $3.10 a share, below the FactSet consensus estimate of $3.33 a share.
Ahead of Thursday's moves, Crocs's stock had risen about 44% in 2024, ahead of the 15.8% increase by the S&P 500 SPX.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-01-24 0955ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks